3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
3
Neoplasms
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Wilms Tumor
1
Venous Thromboembolism
1
Tuberous Sclerosis
1
Thrombosis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Perioperative Inflammatory Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Margins of Excision
1
Lymphangioleiomyomatosis
1
Interventions
Sunitinib
86
Sorafenib
60
Everolimus
47
pazopanib
46
Bevacizumab
46
Nivolumab
44
pembrolizumab
37
aldesleukin
29
Interferon-alpha
26
Axitinib
24
temsirolimus
23
cabozantinib
20
Interleukin-2
19
Ipilimumab
16
Interferon alpha-2
15
Cyclophosphamide
15
fludarabine phosphate
14
Gemcitabine
14
Peripheral Blood Stem Cell Transplantation
11
Sirolimus
10
Paclitaxel
10
Erlotinib Hydrochloride
10
avelumab
8
Radiosurgery
8
Docetaxel
8
Cyclosporine
8
Capecitabine
8
tremelimumab
7
lenvatinib
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Renal Cell
×
Simvastatin
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled